BTA is no sprinter who crashes after 100 metres, but a long distance runner.
Considering its portfolio of drugs (developed and in development) that range from an anti-flu that improves on Relenza one-hundred fold and treatments for the rhinovirus and Hep C, one can only be proud to be a shareholder in such a company that aims at immeasurably improving and safeguarding the health of humanity. Especially from an ancient, elusive and mutating deadly scourge such as epidemic influenza.
It's a company that showcases the innovative brilliance that can be achieved by Australia's brightest and best and deserves the continuing support of its partners in success - loyal shareholders.
It's performance cannot fail to disappoint as the managers are not primarily focussed on how much money they pull in but on how well they design and deliver their lifesaving drugs.
Such an attitude guarantees great and enduring success. But it takes time, so hang in there to be around when BTA breasts the finishing tape.
(Sir) Lunchalot Scoffer Extraordinairre
BTA Price at posting:
0.0¢ Sentiment: LT Sell Disclosure: Held
